ARCA Biopharma Alpha and Beta Analysis
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ARCA Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in ARCA Biopharma over a specified time horizon. Remember, high ARCA Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ARCA Biopharma's market risk premium analysis include:
Beta 0.19 | Alpha (0.78) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
ARCA |
ARCA Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ARCA Biopharma market risk premium is the additional return an investor will receive from holding ARCA Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ARCA Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ARCA Biopharma's performance over market.| α | -0.78 | β | 0.19 |
ARCA Biopharma Fundamentals Vs Peers
Comparing ARCA Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ARCA Biopharma's direct or indirect competition across all of the common fundamentals between ARCA Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as ARCA Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ARCA Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing ARCA Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ARCA Biopharma to competition |
| Fundamentals | ARCA Biopharma | Peer Average |
| Return On Equity | -0.2 | -0.31 |
| Return On Asset | -0.14 | -0.14 |
| Current Valuation | 393.23 M | 16.62 B |
| Shares Outstanding | 14.51 M | 571.82 M |
| Shares Owned By Insiders | 1.20 % | 10.09 % |
| Shares Owned By Institutions | 98.80 % | 39.21 % |
| Number Of Shares Shorted | 4.99 M | 4.71 M |
ARCA Biopharma Opportunities
ARCA Biopharma Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Janus Henderson Group Plc of 166042 shares of ARCA Biopharma at 3.5507 subject to Rule 16b-3 | 07/03/2024 |
2 | Acquisition by Janus Henderson Group Plc of 16917 shares of ARCA Biopharma at 3.43 subject to Rule 16b-3 | 07/09/2024 |
3 | Janus Henderson buys 1.43 million worth of ARCA Biopharma shares - Investing.com | 07/12/2024 |
4 | ARCA biopharma Upgraded to Sell by StockNews.com - Defense World | 07/17/2024 |
5 | ARCA biopharma GAAP EPS of -0.18 | 08/01/2024 |
6 | Acquisition by Janus Henderson Group Plc of 5390 shares of ARCA Biopharma at 2.93 subject to Rule 16b-3 | 08/16/2024 |
7 | Were Not Very Worried About ARCA biopharmas Cash Burn Rate | 08/20/2024 |
8 | ARCA biopharma declares 1.59 special dividend | 08/26/2024 |
| ARCA Biopharma dividend paid on 28th of August 2024 | 08/28/2024 |
About ARCA Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ARCA or other delisted stocks. Alpha measures the amount that position in ARCA Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
ARCA Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of ARCA Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ARCA Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ARCA Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ARCA Biopharma. Please utilize our Beneish M Score to check the likelihood of ARCA Biopharma's management manipulating its earnings.
| 23rd of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with ARCA Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in ARCA Stock
If you are still planning to invest in ARCA Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ARCA Biopharma's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |